Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoral/cyclosporine-based immunosuppression.

G A Levy1

  • 1Multi Organ Transplant Program, Toronto General Hospital, University of Toronto, Canada.

Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
|August 4, 1999
PubMed
Summary

Neoral, an improved formulation of cyclosporine (CsA), significantly reduces organ transplant rejection and toxicity. Enhanced monitoring may further improve outcomes, offering a less toxic alternative to tacrolimus.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.

Canadian journal of surgery. Journal canadien de chirurgie·2023
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Donor BMI >30 Is Not a Contraindication for Live Liver Donation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Overexpression of Fibrinogen-Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Live donor liver transplantation: a valid alternative for critically ill patients suffering from acute liver failure.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Living vs. deceased donor liver transplantation provides comparable recovery of renal function in patients with hepatorenal syndrome: a matched case-control study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Area of Science:

  • Immunosuppression in Transplantation
  • Pharmacology of Cyclosporine Formulations

Background:

  • Cyclosporine (CsA) revolutionized organ transplantation (heart, lung, liver, kidney).
  • Sandimmune, an older CsA formulation, presented challenges like poor bioavailability and bile dependency.
  • Intravenous CsA was often required early post-transplant.

Purpose of the Study:

  • To evaluate the benefits of Neoral, a newer CsA formulation.
  • To compare Neoral's efficacy and toxicity with tacrolimus.
  • To explore the impact of improved Neoral monitoring on transplant outcomes.

Main Methods:

  • Clinical comparison of Neoral and tacrolimus in transplant recipients.
  • Assessment of rejection rates, steroid use, and toxicity profiles.
  • Discussion of advanced Neoral monitoring techniques (peak CsA, Cmax, AUC).

Related Experiment Videos

Main Results:

  • Neoral demonstrated a marked reduction in acute cellular rejection.
  • Steroid therapy could be discontinued early post-transplant with Neoral.
  • Neoral exhibited a favorable toxicity profile, being less toxic than tacrolimus.
  • Neoral showed comparable efficacy to tacrolimus.

Conclusions:

  • Neoral offers significant advantages over Sandimmune in organ transplantation.
  • Neoral is an effective and less toxic immunosuppressant compared to tacrolimus.
  • Improved Neoral monitoring holds promise for further enhancing transplant success rates and reducing toxicity.